British Pharmacopoeia Commission March 2026 Meeting

Published 31 March 2026

In early March, the British Pharmacopoeia Commission met for its first meeting of 2026.

A central theme of the discussion was the impact of BP standards on patients, including how the BP can better demonstrate the value of monographs, the usability of its guidance, and the role of quality standards in supporting safe and effective medicines.

Commissioners also approved the publication of the BP 2027, which is scheduled for August 2026. The Commission reviewed laboratory activities and heard from the Secretariat about updates and improvements to the BP’s digital products.

Professor Anthony Harnden, Chair of the MHRA, joined the afternoon session to hear about the Commission’s current priorities and talk about how the BP’s work contributes to patient benefit and how the MHRA can improve the measurement and communication of its valuable work.

(Left to right) Rob Lowe (Vice-Chair of BP Commission), Anna-Maria Brady (Chair of BP Commission), Professor Anthony Harnden (Chair of MHRA), and Steve Hoare (Secretary and Scientific Director of BP Commission).

For more information about the British Pharmacopoeia Commission and its members, visit the Meet the Team page. You can also view the summary minutes of the BPC and other Expert group meetings on the Meetings and minutes page.